The Epidermal Growth Factor receptors (EGFR): A new target for anticancer therapy;Les récepteurs à Epidermal Growth Factor (REGF), une nouvelle cible thérapeutique

Cancer/Radiotherapie

Volumn 7, Issue 3, 2003, Pages 195-199

  Gainet, M ^a   Guardiola, E ^a   Dufresne, A ^a   Pivot, X ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

EGFR; Monoclonal antibodies; Tyrosine kinase inhibitors

Indexed keywords

4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BIBX 1382; CANERTINIB; CETUXIMAB; CGP 75166; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; LAPATINIB; MATUZUMAB; MONOCLONAL ANTIBODY; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; NIMOTUZUMAB; PD 160678; PELITINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RESEARCH; CELL PROLIFERATION; DIGESTIVE SYSTEM CANCER; DRUG RESEARCH; DRUG TARGETING; ENZYME INHIBITION; HUMAN; LYMPHOMA; PRIORITY JOURNAL; REVIEW;

EID: 0038691681     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1278-3218(03)00019-2     Document Type: Article

References (17)

1. Baselga J. The EGFR as a target for anticancer therapy-focus on Cetuximab. Eur J of Cancer 2001;37(Suppl):16-22.
2. Baselga J, Herbst R, LoRusso P, Rischin D, Ranson M, Plummer R, et al. Continous administration of ZD1839 (Iressa®) a novel oral epidermal growth factor receptor tyrosine kinase inhibitor in patients with 5 selected tumor types: evidence of activity and good tolerability. Am J Clin Oncol 2000;19:177.
3. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14.
4. Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P. et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 2000;6:4343-50.
5. Cohen E, Rosen F, Dekker A, Bajda C, Stenson K, Shulman L, et al. Phase II study of ZD1839 (Iressa®) in recurrent or metastatic squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 2002;21:899.
6. Etienne MC, Pivot X, Formento JL, Bensadoun RJ, Formento P, Dassonville O, et al. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluoro-uracil. Br J Cancer 1999;79:1864-9.
7. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-32.
8. Hidalgo M, Malik S, Rowinsky E, Miller A, Duffey D, DeGradfenried L, et al. Inhibition of the epidermal growth factor receptor by Osi-774 specific EGFR inhibitor in malignant and normal tissues of cancer patients. Proc Am Soc Clin Oncol 2001;20:71.
9. Hong W, Arquette M, Nabell L, Needle M, Waksal H, Herbst R. Efficacity and safety of the anti-epidermal growth factor antibody IMC-C225 in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck refractory to cisplatin containing chemotherapy. Am Soc of Med Oncol 2001;20:224.
10. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999;17:259-69.
11. Magné N, Pivot X, Bensadou RJ, Guardiola E, Poissonnet G, Dassonville O, et al. The relationship of the tumoral epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemoradiotherapy. Eur J Cancer 2001;37:2169-77.
12. Nicholson R, Gee J, Harper M. EGFR and cancer prognosis. Eur J Cancer 2001;37(Suppl):9-15.
13. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody Cetuximab® in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-43.
14. Saltz L, Rubin M, Hochster H, Tchekmydian NS, Waksal H, Needle M, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001;20:7.
15. Santini J, Formento JL, Francoual M, Milano G, Schneider M, Dassonville O, et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991;13:132-9.
16. Senzer N, Soulieres D, Siu L, Agarwale S, Vokes E, Hidalgo M, et al. Phase evaluation of Osi-774 a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 2001;20:2.
17. Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, et al. Epidermal Growth Factor Receptor-targeted Therapy with C225 and Cisplatin in Patients with Head and Neck Cancer. Clin Cancer Res 2001;7:1204-13.